ASCO26: David Reardon, MD Glioblastoma Vaccine | Dana-Farber Cancer Institute
🛍️ Products Mentioned (1)
At #ASCO26, Dana-Farber Cancer Institute's Dr. David Reardon reports on data showing a phase 1 trial looking at a personalized vaccine plus pembrolizumab sparked tumor-targeting T cells in glioblastoma and was linked to longer survival in immune responders. Read more here: https://www.dana-farber.org/newsroom/news-releases/2026/dana-farber-researchers-to-present-two-plenary-studies-and-additional-late-breaking-cancer-research-at-2026-asco-0 Video published June 2026.
🎬 More from Dana-Farber Cancer Institute
Understanding Chemo Neuropathy: A Webinar by the Older Adults with GI Cancer Program | Dana-Farber
19 views
Learning About Chronic Lymphocytic Leukemia | Lymph Notes: A Lymphoma Learning Series
112 views
Society of Gynaecological Oncology Congress 2026: Tara Berman, MD | Dana-Farber Cancer Institute
30 views
ASCO26: Julia Rotow, MD Silevertinib in Lung Cancer | Dana-Farber Cancer Institute
55 views
ASCO26: Atish Choudhury, MD, PhD A-DREAM/Alliance A032101 | Dana-Farber Cancer Institute
38 views
ASCO26: Sara Tolaney, MD, MPH ASCENT-04 | Dana-Farber Cancer Institute
77 views